HitGen Receives New Funding to Discover Novel Therapeutics for Underserved Diseases
Summary
HitGen secured new funding from the Gates Foundation to advance drug discovery for underserved diseases. The company will use its DNA-encoded library platform to find novel drug leads for tuberculosis, malaria, and non-hormonal contraception. The agreement covers screening against 15 drug targets identified with partners in academia and research institutes. HitGen positions its platform as a tool for early-stage small-molecule discovery and says it supports collaborations with biopharma organizations worldwide.
Funding
Amount
None
Total raised
Date
November 20, 2025
Announcement date
Investors
Bill & Melinda Gates Foundation, Shanghai Stock Exchange
Lead investors
Company
hitgen.com
Funded company
Classifications
industries
No industries detected
applications
Data Mining
AskAI Classifications
Labels
No AI classifications detected